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Objectives: Sepsis lacks a reliable and readily
available measure of disease activity. Thereby, it
remains unclear how to monitor response to
treatment. Research on numerous (new) biomarkers
associated with sepsis provided disappointing results
and little is known about changes in vital signs
during sepsis resuscitation. We hypothesised that
trends in vital signs together with routine biomarker
levels during resuscitation might provide information
about the response to treatment at a very early stage
of sepsis in the emergency department (ED). We
therefore explore trends in vital signs and routine
biomarker levels during sepsis resuscitation in
the ED.
Design: Prospective observational pilot study.
Setting: ED of a tertiary care teaching hospital.
Participants: 99 Adult non-trauma patients with
suspected infection and 2 or more systemic
inflammatory response syndrome criteria admitted to
the ED.
Primary and secondary outcome measures:
Vital signs and biomarker levels at admittance (T0)
and after 3 h in the ED (T1).
Results: In total, data of 99 patients were analysed.
Of these patients, 63 presented with sepsis, 30 with
severe sepsis and 6 with septic shock. All vital signs
decreased, except for peripheral oxygen saturation
which increased. Almost all routine biomarker levels
decreased during resuscitation, except for C reactive
protein, bands, potassium, troponin T and direct
bilirubin which remained stable. Sodium, chloride and
N-terminal prohormone of brain natriuretic peptide
increased slightly.
Conclusions: Vital signs and biomarker levels
showed descending trends during resuscitation,
except for parameters directly affected by treatment
modalities. Despite these trends, most patients
improved clinically. Trends in vital signs and routine
biomarkers might be helpful in predicting clinical
course and response to treatment in patients with
sepsis during early resuscitation.
INTRODUCTION
Early and aggressive resuscitation is an
important factor to reduce mortality of
sepsis.1 2 It appears that early recognition of
patients with sepsis and timely and aggressive
resuscitation are more important than the
speciﬁc kind of treatment provided.1 3 4
Sepsis lacks a reliable measure of disease
activity, similar to the viral load in HIV or left
ventricle function in cardiology.5 6
Therefore, it remains unclear how response
to treatment can be monitored.6 7 One
known approach to monitor this is to
monitor the patient’s vital signs. However,
there is little information about changes in
vital signs in sepsis and their relation to treat-
ment during early resuscitation in the emer-
gency department (ED). Furthermore,
numerous biomarkers associated with sepsis
have been studied for this purpose, generally
with disappointing results. Their sensitivity
Strengths and limitations of this study
▪ Our pilot study is the first to look at trends in
vital signs and biomarker levels during sepsis
resuscitation in the emergency department.
▪ Our pilot study shows that there are significant
trends in vital signs and biomarker levels during
resuscitation, and that these trends might poten-
tially serve as a guide for treatment or to
measure disease activity.
▪ Our pilot study was not designed to find the
cause of the trends: trends might or might not
have evolved as a result of the treatment
provided.
▪ The measurement interval of 3 h chosen in this
study might not be the optimal one; we recom-
mend a follow-up study to find the optimal inter-
val between measurements.
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and speciﬁcity are too low to be of real clinical value
and they are often not readily available.7 8
Up to 50% of all patients with sepsis are admitted
through the ED.9 Patients are usually transferred from
the ED to either the intensive care unit (ICU) or
nursing wards within 4 h.10 11 Within these 4 h, early
resuscitation is initiated, preferably as soon as possible.6
We hypothesise that trends in vital signs together with
routine biomarker levels during the resuscitation of
patients with sepsis in the ED might provide information
about the response to treatment. This information is
useful to guide treatment at a very early stage of sepsis,
while the patient is still in the ED. The response to treat-
ment could be used to tailor the patient’s treatment and
monitoring and, at the same time, prevent doing harm
to patients with mild sepsis with too aggressive treat-
ment. It could furthermore serve as a feasible and accur-
ate way to recognise the patients with a great chance to
deteriorate and potentially provide an early warning of
deterioration.12 To the best of our knowledge, there are
no data available about trends in vital signs and biomar-
kers during resuscitation in the ED. Therefore, we per-
formed a pilot study within the 4 h time frame that the
patient is in the ED.
METHODS
Study design and setting
We performed a prospective observational pilot study in
the ED of the University Medical Center Groningen, a
tertiary care teaching hospital with over 34 000 visits to
the ED annually. The pilot study was aimed to establish
power calculations and feasibility of a full-scale study on
the use of trends in vital signs and biomarkers as
response to treatment parameter. The pilot aimed to
include a convenience sample of 100 patients within a
limited 6-month time frame. Data were collected
between October 2013 and April 2014. To prevent selec-
tion bias, taking blood samples in patients with an
altered mental status due to sepsis was also approved by
the review board. In these cases, informed consent was
obtained from the next of kin or from the patient
during their stay in hospital.
Study population and protocol
Adult non-trauma patients visiting the ED with pre-
sumed infection or sepsis were screened for inclusion.
Inclusion criteria were: age ≥18 years, presumed or con-
ﬁrmed infection, and two or more systemic inﬂamma-
tory response syndrome (SIRS) criteria as deﬁned by the
International Sepsis Deﬁnitions Conference.13
Patients are usually transferred from the ED to either
the ICU or nursing ward within 4 h. To detect trends in
vital signs and biomarker levels, we took measurements
at two points within this time frame: at admittance to
the ED (T0) and after 3 h (T1). At T0, a nurse measured
the patient’s vital signs and took a routine blood sample.
Vital signs were measured with a patient monitor
(IntelliVue MP30 System with Multi-Measurement
Module, Philips, Eindhoven, The Netherlands), except
for temperature which was measured using an electronic
tympanic ear thermometer (Genius 2; Mountainside
Medical Equipment, Marcy, New York, USA).
Simultaneously with the routine blood sample, the nurse
took a number of additional blood vials for this study.
These additional vials were temporarily stored until
informed consent was obtained. This procedure ensured
that treatment was not delayed for patients participating
in the study. The vials for the routine blood sample
were immediately sent to the hospital’s central labora-
tory and were analysed for the routine biomarkers listed
in table 1.
Patients or their healthcare proxies had to provide
written informed consent before T1; otherwise, the
patient was excluded from the study and the stored vials
were destroyed. The stored vials were sent to the central
laboratory for analysis immediately after obtaining
informed consent. The blood in these vials was analysed
for four additional routinely available biomarkers, as
shown in table 1. These biomarkers were added for the
following reasons: N-terminal prohormone of brain
natriuretic peptide (NT pro-BNP) as a marker for ﬂuid
overload, cortisol as a marker for stress response,
D-dimer for coagulation status and marker of dissemi-
nated intravascular coagulation and troponin T as a
marker of myocardial damage.
At T1, new blood samples were collected and immedi-
ately analysed for all biomarkers shown in table 1. The
patient’s vital signs were also recorded at T1 using the
same procedures and equipment as at T0. Furthermore,
we recorded the amount of intravenous ﬂuids given to
the patient in the ED until T1. In case a patient was
transferred to the ICU or a ward before T1, a researcher
took the T1 blood samples and vital signs there accord-
ing to the study protocol.
The attending physician was asked for the suspected
focus of sepsis at the moment the patient was trans-
ferred out of the ED and was allowed to select multiple
options. Demographic data were collected from the
patient’s electronic medical records. All patients
received treatment according to the routine sepsis
protocol, including ﬂuid resuscitation, antibiotics and
supplemental oxygen. According to protocol, ﬂuid
resuscitation was performed by an initial ﬂuid challenge
of 500 mL saline solution (NaCl 0.9%) in 10 min, fol-
lowed by 500 mL every 15 min until a mean arterial
pressure (MAP) of >65 mm Hg was reached.6 When the
MAP was still <65 mm Hg after 2 L of saline, an intensi-
vist was consulted to transfer the patient to the ICU and
start inotropic medication. From previous studies in our
department, we know that the median time to start
ﬂuid resuscitation was 21 min (sepsis 26, severe sepsis
15 and septic shock 4 min). Antibiotics were given in
accordance with the guidelines provided by the Dutch
Working Party on Antibiotic Policy (SWAB).14 The
median time to intravenous antibiotics was 61 min
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(sepsis 75, severe sepsis 54 and septic shock 45 min)
from ED entrance in previous sepsis studies in our
department. Supplemental oxygen was given to main-
tain an SaO2 between 94% and 98%. The treatment
protocol did not change during the inclusion period of
the study.
Statistical methods
Continuous data are presented as mean with SD or
median with IQR depending on their distribution.
Normality was tested using the Shapiro-Wilk test for nor-
mality. Categorical data are presented as absolute
numbers with percentages. The Wilcoxon-related
samples signed rank test was used for comparison of bio-
marker levels and vital signs between T0 and T1. Effect
sizes are presented as Cohen’s d.15 The variance
between the sepsis severity groups and effect of medica-
tion or comorbidities on the response to treatment was
tested using the non-parametric Jonckheere-Terpstra
test. Missing data were excluded for analysis. All statis-
tical analyses were performed using IBM SPSS Statistics
for Windows V.22.0 (IBM Corp, Armonk, New York,
USA). A p value of <0.05 was considered signiﬁcant; all
tests were two tailed.
RESULTS
In total, 101 patients were included. Two patients were
excluded since informed consent could not be obtained
from one patient before T1 and was withdrawn by
another patient. The remaining 99 patients were
included in the ﬁnal analysis. Of these patients, 63 pre-
sented with sepsis, 30 with severe sepsis and 6 with
septic shock at ED admission. Patient characteristics,
including comorbidities and medication use prior to
ED presentation, are shown in table 2. Patients with
severe sepsis more frequently had a history of mild liver
disease (p=0.02). Patients with sepsis used diuretics
more often (p=0.02). The presumed focus of infection,
vital signs and treatment parameters are shown in
table 3. The most frequent foci were pulmonic and uro-
genital. The frequency of these foci did not differ
between severity groups. Patients in the septic shock
group received more intravenous ﬂuids (3.5 L; IQR
2.9–5.0 L) compared with those with severe sepsis and
those with sepsis (p=0.009).
Vital signs
Blood pressure at T0 and T1 was inversely related to
sepsis severity as blood pressure decreased with
Table 1 Overview of the measured biomarkers and their characteristics
Name Unit CV (%) Reference values
Routine biomarkers
Albumin g/L 1.4 35–50
ALP U/L 2.2 Male: <115, female: <98
AST U/L 1.4 Male: <35, female: <31
Bands % n/a 0–3
Bilirubin, direct µmol/L 1.9 <5
Bilirubin, total µmol/L 1.9 <17
Calcium mmol/L 1.4 2.20–2.60
Chloride mmol/L 0.8 97–107
Creatinine µmol/L 2.0 Male: 50–110, female: 50–90
CRP mg/L 3.0 <5
γ-GT U/L 1.9 Male: <55, female: <38
Glucose mmol/L 1.5 4.0–5.5 (fastening)
Hb mmol/L 1.3 Male: 8.7–10.6, female: 7.5-–9.9
Lactate mmol/L 1.5 0.5–2.2
LDH U/L 1.3 Male: <248, female: <247
Leucocytes 109/L 1.8 4–10
Potassium mmol/L 0.8 3.5–5.0
Sodium mmol/L 0.7 135–145
Thrombocytes 109/L 4.4 150–350
Urea mmol/L 2.5 2.5–7.5
Study-specific additional biomarkers
Cortisol nmol/L 3.8 08:00:200–800
16:00:100–400
22:00:50–200
D-dimer ng/mL 4.5 <500
hs-Trop T ng/L 5.0 <14
NT pro-BNP ng/L 2.2 <175, >75-year: <450
γ-GT, γ-glutamyl transferase; ALP, alkaline phosphatase; AST, aspartate transaminase; CRP, C reactive protein; CV, averaged interassay and
intra-assay coefficient of variation during the study inclusion period; Hb, haemoglobin; hs-Trop T, high-sensitivity troponin T; LDH, lactate
dehydrogenase; NT pro-BNP, N-terminal prohormone of brain natriuretic peptide.
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increasing severity of sepsis. The results of all vital sign
measurements are shown in tables 3 and 4. Table 2
shows the vital signs for T0 and T1 separated by the
sepsis severity groups. Table 4 includes the δ’s between
T0 and T1 for each vital sign; these are also graphically
represented in ﬁgure 1. We found signiﬁcant differences
for all measured vital signs. As becomes apparent from
ﬁgure 1, all vital signs decreased during the measure-
ment time frame, except for peripheral oxygen satur-
ation which increased by 1.1%. The heart rate and
respiratory rate dropped by >10% during resuscitation
(p<0.001). At the same time, the systolic blood pressure
decreased by 5% and diastolic blood pressure decreased
by >9% (p<0.001).
Biomarkers
The results for the biomarker levels are shown in
table 4, including δ’s between T0 and T1 for each bio-
marker. These δ’s are also shown in ﬁgure 2. Almost all
routine biomarkers levels decreased during resuscitation
in the ED, except for C reactive protein (CRP), bands,
potassium and direct bilirubin which remained stable.
Levels of sodium and chloride increased slightly by 0.8%
and 2.1% (p<0.001), respectively. The levels of NT
pro-BNP increased by 3.0% (p=0.039) during resuscita-
tion. Cortisol and D-dimer levels decreased by 20.1%
(p<0.001) and 3.7% (p=0.039), respectively. The high-
sensitivity troponin T (hs-Trop T) levels did not show a
signiﬁcant trend.
Table 2 Patient characteristics, comorbidity, medication at presentation in the emergency department
N Overall Sepsis Severe sepsis Septic shock
p Value99 99 (100.0%) 63 (63.6%) 30 (30.3%) 6 (6.1%)
Demographics
Age† 99 59 (47–70) 60 (49–70) 56 (44.5–73.3) 56.5 (47–68.8) 0.50
Gender
Male* 99 57 (57.6%) 29 (46.0%) 23 (76.7%) 5 (83.3%) 1.00
Female* 99 42 (42.4%) 34 (54.0%) 7 (23.3%) 1 (16.7%) 1.00
Comorbidity
Myocardial infarction* 99 13 (13.1%) 11 (17.5%) 2 (6.7%) 0 (0%) 0.08
Congestive heart failure* 99 6 (6.1%) 5 (7.9%) 1 (3.3%) 0 (0%) 0.29
Peripheral vascular disease* 99 6 (6.1%) 4 (6.3%) 2 (6.7%) 0 (0%) 0.80
Cerebrovascular disease* 98 12 (12.1%) 9 (14.3%) 2 (6.7%) 1 (16.7%) 0.44
Dementia* 99 3 (3.0%) 2 (3.2%) 1 (3.3%) 0 (0%) 0.86
Chronic pulmonary disease* 99 23 (23.2%) 17 (27.0%) 14 (13.3%) 2 (33.3%) 0.33
Connective tissue disease* 99 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.00
Ulcer disease* 99 2 (2.0%) 1 (1.6%) 1 (3.3%) 0 (0%) 0.76
Mild liver disease* 99 11 (11.1%) 3 (4.8%) 8 (26.7%) 0 (0%) 0.02‡
Diabetes* 99 16 (16.2%) 12 (19.0%) 4 (13.3%) 0 (0%) 0.25
Hemiplegia* 99 2 (2.0%) 1 (1.6%) 1 (3.3%) 0 (0%) 0.76
Moderate or severe renal disease* 99 23 (23.2%) 11 (17.5%) 10 (33.3%) 2 (33.3%) 0.08
Diabetes with end-organ damage* 99 3 (3.0%) 2 (3.2%) 1 (3.3%) 0 (0%) 0.86
Any tumour* 99 30 (30.3%) 20 (31.7%) 9 (30.0%) 1 (16.7%) 0.60
Leukaemia* 99 5 (5.1%) 3 (4.8%) 2 (6.7%) 1 (16.7%) 0.92
Lymphoma* 99 7 (7.1%) 6 (9.5%) 1 (3.3%) 0 (0%) 0.20
Moderate or severe liver disease* 99 4 (4.0%) 1 (1.6%) 3 (10.0%) 0 (0%) 0.16
Metastatic solid tumour* 99 8 (8.1%) 6 (9.5%) 2 (6.7%) 0 (0%) 0.44
AIDS* 99 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.00
Charlson Index† 99 2 (1–4) 2 (1–4) 2 (2–4) 1 (1–2) 0.80
Medication at emergency department presentation
RAS inhibitor* 99 25 (25.3%) 16 (25.4%) 5 (16.7%) 4 (66.7%) 0.70
β-blocker* 99 34 (34.3%) 21 (33.3%) 10 (33.3%) 3 (50.0%) 0.69
Calcium-channel blocker* 99 15 (15.2%) 12 (19.0%) 2 (6.7%) 1 (16.7%) 0.19
Antibiotic* 99 30 (30.3%) 19 (30.2%) 10 (33.3%) 1 (16.7%) 0.93
Immunosuppressive medication* 99 33 (33.3%) 19 (30.2%) 13 (43.3%) 1 (16.7%) 0.51
Diuretic* 99 24 (24.2%) 20 (31.7%) 4 (13.3%) 0 (0%) 0.02‡
Non-steroid anti-inflammatory drug* 99 32 (32.3%) 23 (36.5%) 9 (30.0%) 0 (0%) 0.16
Paracetamol* 99 18 (18.2%) 11 (17.5%) 7 (23.3%) 0 (0%) 0.99
Antidiabetic medication* 99 17 (17.2%) 13 (20.6%) 4 (13.3%) 0 (0%) 0.19
Data are presented as:
*Absolute number and percentage.
†Median and IQR.
‡Significant result.
RAS, renin angiotensin system.
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Table 3 Presumed focus, vital signs and treatment parameters in the emergency department
N Overall Sepsis Severe sepsis Septic shock
p Value99 99 (100.0%) 63 (63.6%) 30 (30.3%) 6 (6.1%)
Presumed focus
Respiratory* 99 49 (49.5%) 31 (49.2%) 13 (43.3%) 5 (83.3%) 0.71
Urogenital* 99 31 (31.3%) 21 (33.3%) 8 (26.7%) 2 (33.3%) 0.61
Skin/soft-tissue/wound* 99 6 (6.1%) 4 (6.3%) 2 (6.7%) 0 (0.0%) 0.80
Intra-abdominal* 99 21 (21.2%) 13 (20.6%) 6 (20.0%) 2 (33.3%) 0.76
Catheter/tube/implant* 99 3 (3.0%) 2 (3.2%) 1 (3.3%) 0 (0.0%) 0.86
Meningitis* 99 1 (1.0%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0.46
Other or unknown focus* 99 15 (15.2%) 10 (15.9%) 4 (13.3%) 1 (16.7%) 0.82
Vital signs
T0: Heart rate (bpm)† 99 110 (100–120) 110 (100–120) 112.5 (104.5–120.8) 113.5 (93.5–136.8) 0.66
T1: Heart rate (bpm)† 93 98 (90–108.5) 98 (89–110) 100 (94.3–105) 100 (88.8–138) 0.71
T0: Systolic blood pressure (mm Hg)‡ 99 124.1±21.87 128.9±18.96 123.3±17.63 78.2±17.00 0.002§
T1: Systolic blood pressure (mm Hg)‡ 91 115.4±19.09 119.7±17.84 112.3±17.41 89.8±17.66 0.002§
T0: Diastolic blood pressure (mm Hg)‡ 99 71.5±15.58 73.4±14.48 71.7±15.63 50.2±12.22 0.03§
T1: Diastolic blood pressure (mm Hg)‡ 91 64.6±13.32 65.3±12.50 64.9±15.46 55.5±7.01 0.27
T0: MAP (mm Hg)‡ 99 89.2±15.98 91.9±14.01 89.4±14.71 59.67±13.32 0.02§
T1: MAP (mm Hg)‡ 91 81.5±14.12 83.5±13.05 80.3±15.38 67.2±10.23 0.02§
T0: Respiration rate (breath/min)† 93 23 (18–28) 23 (18–27.3) 23 (18–27.5) 29 (21–34.8) 0.31
T1: Respiration rate (breath/min)† 86 20 (17.8–24) 20 (18–27) 20 (18.8–24) 24 (14.3–34.3) 0.27
T0: Oxygen saturation (%)† 98 96 (93–98) 95 (93–98) 96 (92.8–98) 94 (86.5–98) 0.88
T1: Oxygen saturation (%)† 89 97 (95–98.5) 97 (96–98) 97 (95.3–99) 96 (93.5–97.3) 0.72
T0: Temperature (°C)† 99 38.4 (37.5–38.9) 38.4 (37.7–38.9) 38.6 (37.8–39.0) 36.9 (34.5–38.8) 0.58
T1: Temperature (°C)† 91 37.7 (36.8–38.6) 37.7 (37.1–38.5) 37.7 (36.6–38. 8) 36.6 (36.6–39.2) 0.60
Treatment parameters
Intravenous fluids (L)† 98 1.0 (0.5–2.0) 1.0 (0.5–1.5) 1.0 (0.9–2.0) 3.5 (2.9–5.0) 0.009§
T0: Supplemental oxygen (L)† 99 0.0 (0.0–2.0) 0.0 (0.0–2.0) 0.0 (0.0–2.0) 2.0 (0.0–15.0) 0.74
T1: Supplemental oxygen (L)† 87 2.0 (0.0–3.0) 2.0 (0.0–3.0) 0.0 (0.0–2.5) 13.5 (1.5–15.0) 0.25
Data are presented as:
































Table 4 The δ in vital signs and biomarker levels between T0 and T1
N T0 N T1 δ (T1–T0) p Value d
Vital signs
Heart rate (bpm)† 99 110 (100 to 120) 93 98 (90 to 108.5) −10 (−17.5 to −4.0) <0.001§ −0.75
Systolic blood pressure (mm Hg)* 99 124.1±21.87 91 115.4±19.09 −7.5±19.02 <0.001§ −0.38
Diastolic blood pressure (mm Hg)* 99 71.5±15.58 91 64.6±13.32 −6.4±13.37 <0.001§ −0.44
MAP (mm Hg)* 99 89.2±15.98 91 81.5±14.12 7.0±13.86 <0.001§ −0.46
Respiration rate (breath/min)† 93 23 (18 to 28) 86 20 (17.8 to 24) −2 (−6 to −2) 0.003§ −0.32
Oxygen saturation (%)† 98 96 (93 to 98) 89 97 (95 to 98.5) 1.0 (−1.0 to 5.0) 0.001§ −0.35
Supplemental oxygen (L)† 99 0.0 (0.0 to 2.0) 87 0.0 (0.0 to 3.0) 0.0 (0.0 to 2.0) <0.001§ −0.40
Temperature (°C)† 99 38.4 (37.5 to 38.9) 91 37.7 (36.8 to 38.6) −0.4 (−1.0 to 0.3) <0.001§ −0.41
Routine biomarkers
Albumin (g/L)† 93 37 (35 to 40.5) 98 34 (31.8 to 37) −3.0 (−5.0 to −1.0) <0.001§ −0.78
ALP (U/L)† 97 83 (55 to 136) 98 71.5 (48.8 to 115.5) −9.0 (−14.8 to −3.0) <0.001§ −0.77
AST (U/L)† 98 26 (20 to 38.3) 98 24 (18 to 36.3) −2.0 (−4.5 to −0.0) <0.001§ −0.56
Bands (%)† 82 0.0 (0.0 to 2.3) 97 0.0 (0.0 to 3.5) 0.0 (0.0 to 0.0) 0.72 −0.04
Bilirubin, direct (µmol/L)† 97 4 (3 to 8) 98 4 (3 to 9) 0.0 (−1.0 to 1.0) 0.36 −0.09
Bilirubin, total (µmol/L)† 97 12 (8 to 18) 98 11 (8 to 16) −1.0 (−2.0 to 0.0) <0.001§ −0.41
Calcium (mmol/L)† 92 2.23 (2.14 to 2.30) 98 2.09 (1.98 to 2.20) −0.1 (−0.2 to −0.08) <0.001§ −0.78
Chloride (mmol/L)† 92 100 (96 to 102) 98 102 (99 to 106) 2.0 (1.0 to 4.0) <0.001§ −0.78
Creatinine (µmol/L)† 99 85 (64 to 123) 98 83.5 (63.5 to 128.3) −1.5 (−8.0 to 4.0) 0.02§ −0.24
CRP (mg/L)† 99 93 (36 to 201) 98 99.5 (45.8 to 184.3) 0.0 (−12.3 to 8.5) 0.45 −0.08
γ-GT (U/L)† 96 46 (26.5 to 106.5) 98 39.5 (24.8 to 92.8) −4.0 (−12.0 to −1.0) <0.001§ −0.70
Glucose (mmol/L)† 99 7.1 (6.1 to 8.6) 97 6.7 (5.9 to 7.7) −0.5 (−1.2 to 0.3) 0.001§ −0.34
Haemoglobin (mmol/L)† 99 7.9 (6.9 to 8.7) 99 7.3 (6.5 to 8.2) −0.6 (−0.8 to −0.2) <0.001§ −0.79
Lactate (mmol/L)† 86 1.6 (1.08 to 2.1) 96 1.2 (0.9 to 1.7) −0.2 (−0.8 to 0.1) <0.001§ −0.39
LDH (U/L)† 98 212 (163 to 257.5) 98 177 (142.5 to 232.8) −21.0 (−41.0 to −8.0) <0.001§ −0.69
Leucocytes (109/L)† 99 12.1 (8.4 to 20.4) 99 11.9 (7.9 to 17.0) −0.6 (−1.6 to 0.4) 0.005§ −0.28
Potassium (mmol/L)† 98 3.9 (3.5 to 4.3) 97 3.8 (3.5 to 4.3) 0.0 (−0.3 to 0.2) 0.28 −0.11
Sodium (mmol/L)† 98 137 (133 to 139) 98 138 (134 to 140.3) 1.0 (0.0 to 3.0) <0.001§ −0.59
Thrombocytes (109/L)† 99 208 (163 to 284) 99 188 (143 to 259) −15.0 (−29.0 to −3.0) <0.001§ −0.63
Urea (mmol/L)† 99 7.2 (4.8 to 12.2) 98 6.8 (4.1 to 12.1) −0.4 (−0.8 to −0.1) <0.001§ −0.64
Study-specific additional biomarkers
Cortisol (nmol/L)† 91 860 (505 to 1245) 90 765 (366.3 to 1150) −127.5 (−352.5 to −20.0) <0.001§ −0.43
D-dimer (ng/mL)† 92 735 (354 to 2274) 90 779 (357 to 2403) −44 (−171 to 23) 0.003§ −0.32
hs-Trop T (ng/L)† 92 20 (8.3 to 39) 92 23 (8.3 to 40.8) −0.5 (−3.0 to 3.0) 0.68 −0.04
NT pro-BNP (ng/L)† 93 409 (143 to 2036) 91 483 (155 to 2788) 10.0 (−21.0 to 169.0) 0.04§ −0.22
Data are presented as:




γ-GT, γ-glutamyl transferase; ALP, alkaline phosphatase; AST, aspartate transaminase; CRP, C reactive protein; hs-Trop T, high-sensitivity troponin T; LDH, lactate dehydrogenase; MAP, mean




























Biomarker levels were below the laboratory’s lower
detection limit in several instances. In these instances,
their value was set to half the lower detection limit.
Direct bilirubin levels were below the detection limit
(1.0 µmol/L) in ﬁve cases at T0 and three cases at T1,
D-dimer levels (detection limit: 150 ng/mL) in ﬁve cases
at T0 and seven cases at T1, hs-Trop T levels (detection
limit: 3.0 ng/L) in three cases at T0 and ﬁve cases at T1.
During the calculation of the δ’s, the T0 values of the
biomarkers were zero in a few cases. To avoid division by
zero problems during the calculation of the percentual
difference, these values were handled as missing data.
Band levels were zero in ﬁve instances at T0 and in one
instance the trombocyte level was zero at T0, these six
instances have been excluded from analysis.
Medication and comorbidity
To explore confounding factors that might have affected
the response to treatment, we analysed associations
between medication use at ED presentation, comorbidity
and the measured vital signs and biomarker levels. The
use of antihypertensive medication did not have a sig-
niﬁcant effect on the changes in vital signs, although
trends in NT pro-BNP levels showed higher ascending
trends in patients using renin angiotensin system (RAS)
inhibitors (median 8.7%, IQR 3.1–37.2%) compared
with patients who did not use RAS inhibitors (median
0.2%; IQR −10.5% to 14.1%; p=0.024). NT pro-BNP
levels also showed higher ascending trends in patients
with congestive heart disease (median 23.1%, IQR 5.2–
37.1%) compared with patients without (median 1.0%,
IQR −10.2% to 13.0%; p=0.006). Patients using diuretics
also had higher ascending trends in NT pro-BNP levels
(median 14.8%, IQR 1.7–41.2%) compared with patients
without diuretics (median 0.2%, IQR −11.3% to 10.9%;
p=0.004). However, patients using diuretics (median
1.0 L, IQR 0.5–1.0 L) received less ﬂuid resuscitation
(median 1.5 L, IQR 1.0–2.1 L; p=0.004). The change in
body temperature was not affected by the antipyretic
effect of NSAIDs. However, in patients using paraceta-
mol, an ascending trend in body temperature (median
0.8%, IQR −1.8% to 1.8%) was observed, while patients
without paracetamol showed a descending trend in body
temperature (median −1.4%, IQR −2.8% to 0.3%;
p=0.021).
The use of antibiotics prior to ED presentation did
not affect the response to treatment of the infection
parameters (leucocytes, CRP); neither was the leucocyte
Figure 1 The δ in vital signs between T0 and T1. SaO2,
peripheral oxygen saturation.
Figure 2 The δ in biomarker levels between T0 and T1. γ-GT, γ-glutamyl transferase; ALP, alkaline phosphatase; AST, aspartate
transaminase; CRP, C reactive protein; CV, averaged interassay and intra-assay coefficient of variation during the study inclusion
period; Hb, haemoglobin; hs-Trop T, high-sensitivity troponin T; LDH, lactate dehydrogenase; NT pro-BNP, N-terminal
prohormone of brain natriuretic peptide.
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response associated with the use of immunosuppressive
medication. However, users of immunosuppressive medi-
cation (median 3.7%, IQR −4.8% to 43.0%) showed a
tendency of ascending CRP levels (median −1.4%, IQR
−40.1% to −5.8%; p=0.017). An effect of immunosup-
pressive or other medication on cortisol levels was not
found.
Patients with congestive heart failure showed less
decrease in heart rate (median 1.4%, IQR −3.8% to
7.8%; vs median −10.3%, IQR −16.5% to −4.2%;
p=0.006) and had an increasing requirement for supple-
mental oxygen (median 2.0 L, IQR 2.0–3.0 L; vs median
0.0 L, IQR 0.0–2.0 L; p=0.011). We did not ﬁnd an asso-
ciation between chronic obstructive pulmonary disease
(COPD) and the response in oxygen saturation or need
for supplemental oxygen. Patients with metastasised
tumours tended to have increasing D-dimer levels
(median 4.4%, IQR −1.7% to 19.4%; vs median −4.7%,
IQR −16.2% to 3.0%; p=0.023).
DISCUSSION
We performed a pilot study aimed at detecting trends in
vital signs and biomarker levels during the early resusci-
tation of patients with sepsis in the ED. To the best of
our knowledge, no other studies have analysed trends in
vital signs and routine biomarker levels during resuscita-
tion in the ED. Nowak et al16 recently reported the regis-
tration of vital sign data in the ﬁrst 4 h in the ED, but
these data were neither analysed nor reported.
We found a generally descending trend in most of the
vital signs and biomarker levels during the patient’s
resuscitation in the ED. We speciﬁcally noticed descend-
ing trends in blood pressure, despite volume therapy.
We observed this trend also in other (yet unpublished)
studies in our ED. Paradoxically, the patients seem to
improve despite this descending trend. This is sup-
ported by the relatively low in-hospital and 28-day mor-
tality in our study of 5.1% and 3.0%, respectively. (Two
patients died after >28 days in the hospital.) We can
only speculate on the mechanism behind this seemingly
paradoxical trend in blood pressure. During further
analysis, we found that the use of antihypertensive or
diuretic medication prior to ED admittance, as well as a
history of congestive heart failure or myocardial infarc-
tion, did not explain the decrease in blood pressure.
While patients with congestive heart failure did show
less decrease in heart rate, the use of β-blockers did not
affect the change in heart rate. The use of paracetamol
prior to ED presentation led to an increasing trend in
body temperature, perhaps while the antipyretic effect
of paracetamol has worn off during the patient’s stay in
the ED. The descending trend in cortisol levels could
not be explained by comorbidities or medication use
prior to ED presentation; therefore, it is likely that it is
partly inﬂuenced by its circadian rhythm and partly by
the reduction of bodily stress as a response to
treatment.
We found only a few ascending trends; we speculate
that these ascending trends might be a direct result of
the treatment modalities. The only vital sign that showed
an ascending trend was the peripheral oxygen satur-
ation, which is most likely caused by supplementation of
oxygen, reﬂected by higher amounts of supplemental
oxygen at T1. Patients with a history of congestive heart
failure showed an increasing oxygen need, while a
history of COPD did not explain the additional oxygen
requirement. The biomarkers that showed an ascending
trend were sodium, chloride and NT pro-BNP. The
increase in sodium and chloride levels can easily be
explained by the patients receiving intravenous saline
solution (NaCl 0.9%). This might also explain the
increase in NT pro-BNP caused by the increased ven-
tricular volume expansion of the heart. On the other
hand, there might also be a direct association between
NT pro-BNP and the systemic inﬂammatory response.17
Furthermore, we found ascending trends in NT
pro-BNP levels in patients using RAS inhibitors or diure-
tics, although patients using diuretics received less ﬂuid
resuscitation, which might suggest that they had earlier
volume expansion of the heart.
Limitations
The main limitation of our pilot study is that it was not
designed to detect the cause of the trends: trends might
or might not have evolved as a result of the treatment
provided. Detected trends could be inﬂuenced by
several factors such as comorbidity, medication use prior
to ED presentation, treatment parameters, dilution
effects (by intravenous ﬂuids), variation in laboratory
analyses or circadian rhythms. We performed post hoc
tests to explore inﬂuences of comorbidities and medica-
tion use prior to ED presentation in our pilot popula-
tion, as described above. Dilution might play a role, but
we would expect a more even distribution over the dif-
ferent biomarkers when the effects were mainly caused
by dilution. Of the measured biomarkers, only cortisol
has a well-known circadian rhythm. The variance in
laboratory analyses is unlikely to entirely explain the
trends, as reﬂected by the average coefﬁcient of variance
during the study’s inclusion period shown in table 1. All
factors aforementioned need to be taken into account
in further research. Once the clinical value of the trends
has been analysed, they can potentially serve as a guide
for treatment or to measure disease activity.
Recommendations
In our pilot study design, we chose an arbitrary interval
for the vital sign measurements and repeated blood
draw of 3 h. Although trends became apparent during
this time frame, the interval might not be the optimal
one. We recommend that follow-up studies should deter-
mine the optimal interval, with either shorter or longer
intervals between repeated measurements. We are cur-
rently running a follow-up study in patients with sepsis to
detect trends in vital signs measured in 5 min intervals
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during their stay in our ED. In this follow-up study, we
explore the course of vital sign changes in more detail.
Furthermore, we are in the process of designing a new
study, using the results of this pilot study, in which we
will continuously record the patient’s vital signs
beat-to-beat during the ﬁrst 48 h in the hospital. The
latter study should provide valuable insight into the
trends and variability of vital signs in patients with sepsis
and potentially provide an early warning of patient
deterioration.12 Vital signs could also potentially be used
to titrate the amount of ﬂuid resuscitation and supple-
mental oxygen.
The routine biomarkers measured in this pilot study
did, in general, only show relatively minor changes
during the measurement interval. This makes them less
suitable as a response to treatment parameter. The mea-
sured study-speciﬁc biomarkers, except hs-Trop T,
showed larger changes during the measurement inter-
val. We recommend further research to explore their
speciﬁc responses to treatment. We expect that NT
pro-BNP could be a parameter to measure response to
ﬂuid resuscitation and might in the future be used to
titrate the amount of ﬂuids given. Furthermore, cortisol
could be a parameter to measure the body’s stress level
in response to treatment. The levels of D-dimer could
provide information about the status of the coagulation
system and disease activity, especially in patients with
metastasised tumours.
On the basis of our results, we recommend further
exploration of the use of vital signs as a response to
treatment parameter in sepsis. They relatively show the
largest changes within the measurement interval and are
furthermore easily, cheaply and non-invasively
measurable.
We expect that trends with a decrease in heart rate,
respiratory rate and temperature, as well as an increase
in oxygen saturation and blood pressure, could be
valued as a positive response to treatment in patients
with sepsis, although this pilot study could not (yet)
conﬁrm this assumption.
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